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Microarray profiling of invasive breast carcinomas has identified five distinct subtypes of tumors (luminal A,
luminal B, normal breast-like, HER2 overexpressing, and basal-like) that are associated with different clinical
outcomes. The basal-like subtype is associated with poor clinical outcomes and is the subtype observed in
BRCA1-related breast cancers. The aim of this study was to characterize the histologic and immunophenotypic
properties of breast basal-like carcinomas that were first positively identified using DNA microarray analysis.
Detailed histologic review was performed on 56 tumors with known microarray profiles (23 basal-like, 23
luminal, and 12 HER2þ ). Immunohistochemistry for estrogen receptor (ER), HER2, EGFR, smooth muscle actin
(SMA), p63, CD10, cytokeratin 5/6, cytokeratin 8/18, and vimentin was performed on 18 basal-like, 16 luminal,
and 12 HER2þ tumors. The basal-like tumors were grade 3 ductal/NOS (21/23) or metaplastic (2/23) carcinomas
that frequently showed geographic necrosis (17/23), a pushing border of invasion (14/23), and a stromal
lymphocytic response (13/23). Most basal-like tumors showed immunoreactivity for vimentin (17/18), luminal
cytokeratin 8/18 (15/18), EGFR (13/18), and cytokeratin 5/6 (11/18), while positivity for the myoepithelial markers
SMA (4/18), p63 (4/18) and CD10 (2/18) was infrequent. All basal-like tumors tested were ER and HER2.
Morphologic features significantly associated with the basal-like subtype included markedly elevated mitotic
count (Po0.0001), geographic tumor necrosis (P¼ 0.0003), pushing margin of invasion (P¼ 0.0001), and stromal
lymphocytic response (P¼ 0.01). The most consistent immunophenotype seen in the basal-like tumors was
negativity for ER and HER2, and positivity for vimentin, EGFR, cytokeratin 8/18, and cytokeratin 5/6. The
infrequent expression of myoepithelial markers in basal-like carcinomas does not support a direct
myoepithelial cell derivation of these tumors. These findings should further assist in the identification of
basal-like carcinomas in clinical specimens, facilitating treatment and epidemiologic studies of this tumor
subtype.
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Variations in transcriptional programs account for
much of the biological diversity of human cells and
tumors. Despite this molecular diversity, analyses of
invasive breast carcinomas using microarrays have
identified gene expression signatures that charac-
terize many of the essential qualities important
for biological and clinical classification.1–10 DNA
microarray profiling studies on breast tumors show
distinct and reproducible subtypes of breast carci-
noma associated with different outcomes. Expres-
sion profiles have categorized invasive breast
carcinomas into five groups: luminal A, luminal B,
HER2þ /estrogen receptor (ER), basal-like, and
normal breast-like. The basal-like subtype is typi-
cally ER and HER2 (ie not amplified) and shows
some characteristics of breast myoepithelial cells.
The basal-like subtype has been shown to have the
highest proliferation rates and poor clinical out-
comes,2,3 and has also been described in association
with BRCA1-associated carcinomas.11 Overall, little
is known with regard to the development and
prevention of these aggressive tumors.
Normal breast ducts contain at least three types of
epithelial cells: luminal (glandular) cells, basal/
myoepithelial cells, and stem cells. Myoepithelial
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and luminal epithelia can be distinguished by their
different cytokeratin expression patterns. Myo-
epithelial cells typically express cytokeratin 5/6 and
cytokeratin 17, while luminal cells typically express
cytokeratins 8 and 18. Immunohistochemical stu-
dies for basal/myoepithelial and luminal cytokera-
tins appear to be helpful in subtyping invasive
breast carcinomas into distinct biological subtypes,
although the staining patterns for cytokeratins 5/6
and 17 can be highly variable.12
Studies have employed basal/myoepithelial cyto-
keratins and other markers to identify a subset of
ER- and HER2-negative breast carcinomas that are
associated with a poor prognosis, further supporting
the idea that a basal-like phenotype exists.13–18 The
prevalence and poor prognosis of basal-like breast
carcinomas have been validated immunohisto-
chemically; in a 564-case tissue microarray, van de
Rijn et al12 demonstrated that 16% of tumors stained
positive for cytokeratin 5/6 or cytokeratin 17, and
that basal cytokeratin expression was associated
with a poor prognosis. Abd El-Rehim evaluated
1944 cases of invasive breast carcinoma and found
that approximately 18% of tumors show basal
cytokeratin immunoreactivity, and again, these
tumors showed a poor prognosis.14 Tsuda et al17,18
described myoepithelial differentiation in a group of
high-grade invasive ductal carcinomas showing a
large, central acellular zone. These tumors showed
aggressive behavior with increased risk of brain
and lung metastasis. Basal cytokeratins are not
expressed in all tumors classified as basal-like by
gene microarray analysis, which demonstrates a
need to identify other markers of basal-like subtype.
An association between EGFR expression and the
basal-like phenotype has been demonstrated.16
Breast cancers showing immunoreactivity for cyto-
keratin 5/6 were also frequently found to coexpress
EGFR. Nielsen et al13 proposed a panel of four
antibodies (ER, EGFR, HER2, and cytokeratin 5/6) to
identify basal-like tumors in which the basal-like
tumors are identified as those tumors that were ER,
HER2 not amplified, and showed expression of
cytokeratin 5/6 and/or EGFR. It is unknown whether
other basal/myoepithelial markers such as smooth
muscle actin (SMA), p63, or CD10 are expressed in
the basal-like subtype of breast carcinoma. One aim
of this study is to evaluate immunohistochemical
markers that may further facilitate identification
of basal-like tumors in formalin-fixed, paraffin-
embedded tissue.
The morphologic features of breast tumors identi-
fied as basal-like by gene expression profile have not
been well described. It is unclear whether these
tumors are similar or heterogeneous in their histo-
logy and if there are any supportive morphologic
clues to identify this subtype by light microscopy.
Therefore, the second aim of this study was to
evaluate the grade and morphologic features of a
group of known basal-like invasive breast carcino-
mas identified by gene microarray analysis.
Materials and methods
After IRB approval at our institution, 23 basal-like,
23 luminal/ERþ , and 12 HER2þ /ER subtype
invasive breast carcinomas were identified by DNA
microarray analysis as described previously.2,3,19 In
this paper, the tumor subtypes were identified from
three different microarray data sets. In each data set
separately, tumors were subtyped using microarray
expression profiles and hierarchical clustering ana-
lysis of the samples using a breast tumor intrinsic
gene set (see Sorlie et al3 for a detailed description).
Each sample was then classified as being basal-like,
luminal, normal-like, or HER2þ /ER. In all, 18
basal-like, 16 luminal, and 12 HER2þ /ER tumors
had formalin-fixed, paraffin-embedded tissue avail-
able for immunohistochemical studies.
Immunohistochemistry
Sections (5 mm) from formalin-fixed, paraffin-em-
bedded tumors were cut and mounted onto Probe
On Plus slides (Fisher Scientific). Following de-
paraffinization in xylene, slides were rehydrated
through a graded series of alcohol and placed in
running water. Endogenous peroxidase activity
was blocked with 3% hydrogen peroxidase and
methanol. Samples were steamed for antigen retrie-
val with 10 mM citrate buffer (pH 6.0) for 30 min.
Following protein block, slides were incubated with
antibody for ER, HER2, EGFR, SMA, p63, CD10,
cytokeratin 8/18, and vimentin (Table 1), and
incubated with streptavidin-conjugated HRP using
Vectastain ABC kit protocol (Vector Laboratories).
3,30-Diaminobenzidine tetrahydrochloride (DAB)
was used for the visualization of the antibody/
enzyme complex. Slides were counterstained with
hematoxylin (Biomeda-M10) and examined by light
microscopy. Tumor immunoreactivity was scored
0¼negative, 1¼weak positive, and 2¼moderate/
strong positive in combination with the percent of
cells showing positive staining.
Histopathology
Hematoxylin-and-eosin-stained slides from 23
basal-like, 23 luminal/ERþ , and 12 HER2þ /ER
invasive breast carcinomas identified by gene
microarray analysis were evaluated under light
microscopy. The array subtype was blinded at the
time of histologic review. Tumors were evaluated
for grade (1–3) using the modified Scarff–Bloom–
Richardson grading system comprising an architec-
tural grade, nuclear grade, and mitotic grade. Mitotic
counts were performed using the  40 objective on
an Olympus BX51 microscope. Tumors were also
evaluated for tumor histologic type, presence of
geographic necrosis, quantity of apoptotic tumor
cells, border appearance, lymphocytic stromal re-
sponse, nucleoli, nuclear chromatin pattern, apoc-
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rine features, metaplastic features, large central
acellular zone, and medullary features. The histo-
pathologic features of basal-like, luminal/ERþ , and
HER2þ /ER tumors were compared.
Statistical Methods
Fisher’s exact test was used for data categorized
into 2 2 contingency tables. The nonparametric
Jonckheere–Terpstra method was used to test for
ordered differences over categories of interest (such
as tumor array subtype by associated histologic
features or expression of tested immunohistochem-
ical markers). With this test, the null hypothesis is
that the distribution of the response does not differ
across the ordered categories. Statistical analyses
were performed with SAS statistical software,
Version 9.1, SAS Institute Inc., Cary, NC, USA.
Results
Light Microscopic Findings
A detailed morphological analysis of known basal-
like tumors has not been described; therefore, we
performed a morphologic evaluation of 23 basal-like
carcinomas identified by microarray analysis. All
basal-like tumors showed an overall modified
Scarff–Bloom–Richardson grade of 3 (Table 2). The
majority of tumors showed solid architecture with
no tubule formation and a high density of tumor
cells with scant intervening stroma between tumor
cells. In all, 14/23 (61%) tumors showed a pushing
border and 13/23 (56%) had some degree of a
stromal lymphocytic infiltrate at the tumor edge.
Four tumors demonstrated histologic features simi-
lar to those described for atypical medullary
carcinoma (Figure 1a), including a predominantly
pushing border, syncytial arrangement of tumor
cells, and a marked stromal lymphocytic infiltrate
at the tumor edge. Also, 5/23 (22%) tumors showed
regions of ribbon-like architecture with associated
central necrosis (Figure 1b). Most of the tumor cells
contained scant cytoplasm and round to oval nuclei
producing a high nuclear/cytoplasmic ratio. The
nuclear chromatin pattern ranged from coarse to
vesicular. Nucleoli were present in 20/23 (87%)
cases and ranged from inconspicuous to prominent.
A high mitotic rate was identified in all tumors,
ranging from 26 mitoses/10 high-power fields to 92
mitoses/10 high-power fields (average 45 mitoses/10
high-power fields). Geographic zones of necrosis
were identified in 17/23 (74%) (Figure 1c) tumors.
Apoptotic tumor cells were numerous in each of the
cases with geographic necrosis. Two tumors showed
Table 1 Antibody panel used in the study
Antibody Clone Dilution Source Source site
ER 6F11 1:50 Ventana Tuscon, AZ
HER2/neu Hercep test DakoCytomation Carpinteria, CA
EGFR pharmDX DakoCytomation Carpinteria, CA
SMA 1A4 1:50 DakoCytomation Carpinteria, CA
p63 4A4 1:400 Neomarkers Fremont, CA
CD10 56C6 1:40 NovaCastra Newcastle, UK
CK 8/18 Zym5.2 1:75 Zymed South San Francisco, CA
Vimentin V9 1:50 Zymed South San Francisco, CA
CK 5/6 05/16 B4 1:10 Boehringer Mannheim Indianapolis, IN
Table 2 Morphologic features and grade of invasive basal-like, luminal and HER2 carcinomas
Tumor trait Basal-like (n¼23) Luminal (n¼ 23) HER2+/ER (n¼ 12)
Modified SBR overall grade 3 23/23 (100%) 2/23 (9%) 12/12 (100%)
Modified SBR overall grade 1 or 2 0/23 (0%) 21/23 (91%) 0/12 (0%)
Mitoses 425/10 high-power fields 23/23 (100%) 0/23 (0%) 5/12 (42%)
Nucleoli 20/23 (87%) 18/23 (78%) 12/12 (100%)
Geographic necrosis 17/23 (74%) 0/23 (0%) 4/12 (33%)
Vesicular nuclear chromatin 15/23 (65%) 3/23 (13%) 11/12 (92%)
Coarse nuclear chromatin 8/23 (35%) 20/23 (87%) 1/12 (8%)
Pushing border 14/23 (61%) 0/23 (0%) 2/12 (17%)
Infiltrative border 9/23 (39%) 23/23 (100%) 10/12 (83%)
Tumor stromal lymphocytic infiltrate 13/23 (56%) 0/23 (0%) 4/12 (33%)
Apocrine differentiation 0/23 (0%) 0/23 (0%) 0/12 (0%)
Metaplastic features 2/23 (9%) 0/23 (0%) 0/12 (0%)
Atypical medullary features 4/23 (17%) 0/23 (0%) 0/12 (0%)
Central acellular fibrotic zone 0/23 (0%) 0/23 (0%) 0/12 (0%)
SBR¼Scarff–Bloom–Richardson.
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metaplastic components, including squamous me-
taplasia (Figure 1d) and matrix production. None of
the tumors showed appreciable apocrine differentia-
tion or a large, central acellular zone.
Histologic differences were identified among the
basal, luminal, and HER2þ /ER subtypes. The rate
of grade 3 histology seen in the basal-like tumors
(23/23, 100%) was significantly higher than that
observed in the luminal tumors (2/23, 9%),
Po0.0001. When the histologic features of all tumor
subtypes were compared, markedly elevated (425/
10 high-power fields) mitotic index (Po0.001),
geographic tumor necrosis (P¼ 0.0003), pushing
border of invasion (P¼ 0.0001), stromal lymphocytic
response (P¼ 0.01), and atypical medullary features
(P¼ 0.03) were all associated with the basal-like
subtype. The basal-like and luminal tumors were
dissimilar in nearly all evaluated histologic features.
There was overlap in the histology of basal-like and
HER2þ /ER tumors (Table 2); however, metaplas-
tic and medullary tumor features were limited to the
basal-like subtype.
Immunohistochemical Findings
Immunohistochemical stains for ER, HER2, EGFR,
SMA, p63, CD10, cytokeratin 8/18, vimentin, and
cytokeratin 5/6 were performed on 18 basal-like, 16
luminal, and 12 HER2þ /ER invasive breast carci-
nomas identified by gene microarray analysis (Table
3). The basal-like tumors were ER (0/18, 0%) and
HER2 (0/18, 0%), while the luminal subtype
tumors were ERþ (18/18, 100%) and HER2 (0/
18, 0%), and the HER2þ /ER subtype tumors were
ER (0/12, 0%) and HER2 overexpressed (11/12,
92%). The rate of EGFR expression seen in the basal-
like (13/18, 72%) tumors was significantly higher
than that observed in luminal tumors (0/23 0%),
Po0.0001. Most HER2þ /ER (7/12, 58%) subtypes
Figure 1 Morphologic features of basal-like carcinomas. (a) Some tumors showed medullary features, including solid architecture with a
pushing margin and brisk stromal lymphocytic response. (b) Other tumors showed characteristic ribbon-like architecture associated with
central necrosis. (c) Foci of geographic tumor necrosis were a frequent finding in these tumors. (d) One of the two metaplastic carcinomas
showed areas of squamous metaplasia. Original magnification 200 (a–c) and  400 (d).
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also expressed EGFR; thus, in this study, EGFR
expression was seen exclusively in the basal-like
and HER2þ /ER subtypes.
Immunoreactivity for myoepithelial markers with-
in the group of basal-like tumors was highly variable
(Table 3). In all, 4/18 (22%) of the basal-like tumors
showed immunoreactivity for SMA (Figure 2a), with
tumor cell immunoreactivity being distinguished
from the adjacent myofibroblast immunoreactivity.
SMA expression, although infrequent, was asso-
ciated with the basal-like subtype (P¼ 0.02). None
of the luminal or HER2þ /ER tumors showed
immunoreactivity for SMA. Also, 4/18 basal-like
tumors showed immunoreactivity for p63 (Figure 2b).
Immunoreactivity was generally weak to moderate
and present in o5% of the tumor cells. Similar
weak positivity for p63 was also seen in 2/16 (12%)
of luminal tumors and in 4/12 (33%) of HER2þ /
ER tumors. Further, 2/18 (11%) basal-like tumors
showed weak immunoreactivity for CD10, while
Table 3 Summary of immunohistochemical results
MA profile ER HER2 EGFR SMA CD10 p63 CK 8/18 CK 5/6 Vimentin
Basal-like 0/18 0/18 13/18 4/18 2/18 4/18 15/18 11/18 17/18
Luminal 16/16 0/16 0/16 0/16 0/16 2/16 16/16 0/16 1/16
HER2 0/12 11/12 7/12 0/12 1/12 4/12 12/12 1/12 1/12
MA¼microarray, ER¼ estrogen receptor, SMA¼ smooth muscle actin, CK¼ cytokeratin.
Figure 2 Immunophenotype of basal-like carcinomas. (a) SMA and (b) p63 positivity was present in a minority of tumors, with
immunoreactivity being detected in only a small percentage of tumor cells. (c) Most tumors showed strong luminal cytokeratin 8/18
expression throughout the tumor. (e) Vimentin positivity was characterized by strong and diffuse immunoreactivity. Original
magnification 400.
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CD10 expression was also seen in 1/12 (8%) HER2þ
/ER tumors and 0/16 (0%) luminal tumors, and 11/
18 (61%) basal-like tumors showed immunoreacti-
vity for cytokeratin 5/6. Cytokeratin 5/6 expression
in tumors was significantly associated with the
basal-like subtype, P¼ 0.0001. None of the luminal
tumors showed cytokeratin 5/6 expression and 1/12
HER2þ /ER tumors showed weak cytokeratin 5/6
expression. Most tumors, regardless of subtype,
demonstrated expression of luminal cytokeratin 8/
18, including the basal-like tumors, which showed
expression of cytokeratin 8/18 in 15 of 18 (83%)
cases (Figure 2c). Strong cytokeratin 8/18 expression
was identified in all luminal and HER2þ /ER
subtype tumors. In total, 11/18 (61%) basal-like
tumors showed coexpression of both basal and
luminal cytokeratins, which suggests that many of
these tumors show characteristics of both luminal
and basal/myoepithelial cell lineages.
Vimentin expression in tumors was strongly
associated with a basal-like phenotype, Po0.0001,
being present in 17/18 (94%) basal-like tumors. The
positive tumors showed strong, near-diffuse immuno-
reactivity (Figure 2d). In contrast, 1/16 (6%) luminal
tumors and 1/12 (8%) HER2þ /ER tumors showed
weak vimentin expression. The expression pattern
seen in these two tumors was significantly more
focal and weaker than that seen in the basal-like
tumors, suggesting that strong vimentin staining
could be useful for the identification of basal-like
tumors in breast cancers. The overall protein
expression patterns seen in basal-like carcinomas
were heterogeneous. The most common immuno-
phenotype for the basal-like tumors was ER,
HER2, vimentin positive, EGFRþ , cytokeratin
5/6 positive, and cytokeratin 8/18 positive (Table 4).
Strong vimentin and cytokeratin 5/6 expressions
were the most specific markers for the basal-like
subtype.
Discussion
A significant amount of data exists concerning the
histological characteristics of ER tumors and the
immunohistochemical patterns of expression of
nonluminal cell markers (like SMA, p63, vimentin)
in breast carcinomas. The precise relationship
between these features and basal-like tumors, how-
ever, is not known because the only reliable method
to identify basal-like tumors is by microarray
analysis. Therefore, we positively identified a set
of basal-like tumors using microarray analysis and
then performed a histological and immunohisto-
chemical review of their properties.
The morphologic appearance of basal-like tumors
was variable, but some consistent and unique
histologic features were identified when these
tumors were compared to luminal and HER2þ /
ER tumors. Features strongly associated with the
basal-like subtype included markedly elevated mi-
totic rate, geographic tumor necrosis, pushing
margin of invasion, atypical medullary features,
and a stromal lymphocytic response. The basal-like
tumors contained scant cytoplasm producing a high
nuclear/cytoplasmic ratio in which nuclei of
adjacent cells touched or overlapped. The basal-like
tumors were remarkably solid tumors with little
intervening stroma between tumor cells, producing
a densely cellular lesion. The high mitotic index
observed in these tumors is consistent with their
uniformly high expression of the ‘proliferation
cluster’ of genes shown in DNA microarray stu-
dies.1–3 Apocrine differentiation, which is fre-
quently associated with ER-negative status, was
not identified in these tumors.
This study demonstrated that there is overlap in
the histologic features of basal-like and HER2þ /
ER tumors. Both subtypes share histologic features
that have been previously reported as characteristic
of ER breast carcinomas.20 These features include
grade 3 histology and geographic necrosis. Although
there are some histologic features that appear to be
distinctive of basal-like carcinomas, immunohisto-
chemical studies are clearly needed for subtyping
of high-grade breast carcinomas. Additionally, the
morphologic and immunophenotypic features
observed in the basal-like carcinomas (grade 3 histo-
logy, ER/HER2-negative status, and medullary
features) are similar to those reported for BRCA1-
related carcinomas.21,22 These features may even-
tually play a role in risk assessment for BRCA1
mutation screening. The patient BRCA1 mutation
status was not directly addressed in this study, but
all the tumors evaluated were sporadic in nature,
and it is likely that most of the basal-like tumors
were not associated with a BRCA1 mutation.
Table 4 Immunophenotype of invasive basal-like carcinomas
Tumor ER HER2 CD10 p63 SMA CK
5/6
EGFR CK
8/18
Vimentin
1 0 0 0 1 0 1 1 2 2
2 0 0 0 1 0 1 1 2 2
3 0 0 1 1 0 2 2 2 2
4 0 0 0 1 0 1 1 2 2
5 0 0 1 0 0 0 0 0 2
6 0 0 0 0 0 1 2 2 2
7 0 0 0 0 0 2 2 2 0
8 0 0 0 0 0 1 1 2 1
9 0 0 0 0 1 0 1 2 2
10 0 0 0 0 0 0 0 0 2
11 0 0 0 0 0 0 2 2 2
12 0 0 0 0 1 0 2 2 2
13 0 0 0 0 1 0 0 2 2
14 0 0 0 0 1 2 1 2 2
15 0 0 0 0 0 1 2 2 2
16 0 0 0 0 0 0 0 2 2
17 0 0 0 0 0 1 0 0 2
18 0 0 0 0 0 2 2 2 1
0¼negative, 1¼weak positive, 2¼moderate/strong positive, ER¼
estrogen receptor, SMA¼ smooth muscle actin, CK¼ cytokeratin.
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Basal-like breast carcinomas have been character-
ized by gene expression analysis as having a gene
expression pattern similar to basal/myoepithelial
cells found in normal breast tissue (1–3), and
patterns similar to squamous cell carcinomas of
the lung.19 Normal breast myoepithelial cells show
immunoreactivity for basal cytokeratins (ie cyto-
keratins 5, 6, and 17), SMA, CD10, vimentin, and
p63. Studies have shown basal cytokeratin expres-
sion in a subset of invasive breast cancers,12,14 and it
is presumed that most of these tumors are basal-like
tumors; however, these studies did not formally
demonstrate this relationship and other classic
myoepithelial markers were typically not examined.
All of the 18 known basal-like carcinomas in this
study showed an incomplete basal/myoepithelial
cell phenotype. Many, but not all, basal-like tumors
showed expression of cytokeratin 5/6 and EGFR;
however, the majority of basal-like tumors were
negative for myoepithelial markers, including SMA,
CD10, and p63. SMA immunoreactivity, when
present, was only seen in basal-like carcinomas,
but it was infrequent even among this subtype (4/18,
22%). Immunoreactivity for p63 was seen in 22% of
basal-like tumors, but the degree of positivity was
only weak to moderate and typically involved o5%
of tumor cells. It should be noted that p63 expres-
sion was also identified in 2/16 (12%) luminal
breast tumors and 4/12 (33%) HER2þ /ER tumors,
and the immunoreactivity patterns were similar to
the basal-like tumors. SMA, p63, and CD10, there-
fore, appear to be of limited value in the immuno-
histochemical detection of basal-like tumors.
Tumor basal cytokeratin expression was specific
for the basal-like subtype in this study, but 7/18
(39%) of the basal-like tumors were negative for
cytokeratin 5/6 protein expression, as was shown
before.12,13 This finding indicates a need for addi-
tional immunohistochemical markers to identify all
basal-like tumors, and a candidate identified in this
study may be vimentin, which was expressed in
17/18 basal-like tumors. This appeared to be a
distinguishing feature from luminal and HER2þ /
ER subtypes, suggesting that vimentin could be
added to the current panel of antibodies (ER, EGFR,
HER2, and cytokeratin 5/6) used to identify basal-
like tumors; however, the precise combinations and
scoring criteria may need to be re-evaluated and
validated.
Vimentin expression in breast carcinomas may
also have prognostic value and an association with
an aggressive tumor phenotype.23–27 Previous stu-
dies have shown an association between tumor
vimentin expression, a poor prognosis, and ER-
negative status.23,24 Cattoretti et al23 described a
group of ER-negative tumors that often showed
coexpression of vimentin, p53 and EGFR, which is
a phenotype that is very consistent with the basal-
like subtype currently described. We have shown
here and before that many basal-like tumors are
EGFRþ , and Sorlie et al2 showed that most basal-
like tumors are p53 mutated. Domagala et al
demonstrated an inverse relation between vimentin
expression and survival for node-negative breast
cancers (Po0.0001).
The origin of vimentin expression in invasive
basal-like carcinomas is unclear. The possible
mechanisms include direct derivation of these
tumors from myoepithelial cells, epithelial-to-mesen-
chymal transition as a result of dedifferentiation,
and derivation of these tumors from stem cells. The
heterogeneous expression pattern and frequent lack
of expression of myoepithelial markers in these
tumors do not support a direct derivation of these
tumors from myoepithelial cells. Additional evi-
dence against a myoepithelial cell origin is the
cytokeratin 8/18 expression pattern seen in basal-
like tumors. Cytokeratin 8/18 is a marker typically
expressed in the luminal epithelial cells of the
breast and is not expressed in normal myoepithelial
cells. Strong expression of luminal cytokeratin 8/18
was observed in most basal-like tumors (83%) in
this study; 10/18 basal-like tumors also showed
coexpression of both basal/myoepithelial and lumi-
nal cytokeratins, indicative of a mixed basal/luminal
phenotype, and all of these tumors were ER-
negative. The coexpression of basal/myoepithelial
and luminal cytokeratins raises the possibility that
these tumors may arise from stem cells that subse-
quently undergo variable degrees of basal and
luminal differentiation. Studies of the precursor
lesions for these tumors, including hyperplasias and
in-situ carcinomas, will be important in further
evaluating this possibility. These data should assist
in the identification of basal-like tumors in forma-
lin-fixed, paraffin-embedded clinical specimens,
which will be needed for future studies aimed at
evaluating clinical outcomes, treatment responses,
and the epidemiology of this group of tumors.
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